What is TigerConnect?
TigerConnect specializes in developing software solutions designed to enhance care team coordination, automate alerts, streamline message routing, and ultimately improve patient outcomes within healthcare settings. The platform facilitates secure messaging, scheduling, alarm management, patient engagement, and workflow orchestration, serving hospitals and various other care environments. This focus on operational efficiency and patient care positions TigerConnect as a key enabler of digital transformation in the healthcare industry.
How much funding has TigerConnect raised?
TigerConnect has raised a total of $126.1M across 5 funding rounds:
Angel/Seed
$1.9M
Series A
$8.2M
Series B
$21M
Series C
$50M
Series D
$45M
Angel/Seed (2010): $1.9M with participation from Bert Ellis and Herb Madan
Series A (2012): $8.2M led by New Science Ventures and Easton Capital
Series B (2014): $21M supported by OrbiMed, TELUS Corporation, Reed Elsevier Ventures, and Shasta Ventures
Series C (2015): $50M featuring Norwest Venture Partners, Accolade Partners, Reed Elsevier Ventures, Shasta Ventures, OrbiMed, and Invus Group
Series D (2020): $45M backed by Invus, HealthQuest Capital, Norwest Venture Partners, Industry Ventures, Montreux Growth Partners, and New Leaf Ventures
Key Investors in TigerConnect
Norwest Venture Partners
Norwest Venture Partners is a global, multi-stage venture capital and growth equity investment firm founded in 1961, headquartered in Palo Alto, California. They specialize in investing across various stages of company development.
Reed Elsevier Ventures
Reed Elsevier Ventures, established in 2000, is a London-based venture capital firm backed by Reed Elsevier. They focus on investing in visionary entrepreneurs and management teams, actively supporting company growth through their extensive industry network.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, and healthcare services. They support companies at various stages of development.
What's next for TigerConnect?
With a history of consistent capital injections, including major rounds like Series C and Series D, TigerConnect is well-positioned for continued expansion and innovation. The enterprise-level funding context suggests a strategic phase focused on scaling operations, enhancing its platform capabilities, and potentially exploring new market segments or strategic partnerships. The company's sustained access to investment capital indicates strong investor confidence in its business model and its capacity to address critical needs in clinical communication and workflow management.
See full TigerConnect company page
